{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:10:16Z","timestamp":1787497816390,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.leukres.2012.10.021","type":"journal-article","created":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T23:15:58Z","timestamp":1353539758000},"page":"206-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: A systematic review"],"prefix":"10.1016","volume":"37","author":[{"given":"Fabio","family":"Efficace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Cardoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cottone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Mandelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2012.10.021_bib0005","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1200\/JCO.2010.33.2742","article-title":"Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology","volume":"28","author":"Kris","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.10.021_bib0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1200\/JCO.2010.31.3619","article-title":"Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia","volume":"29","author":"Cortes","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.10.021_bib0015","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.10.021_bib0020","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2012.10.021_bib0025","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.10.021_bib0030","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.10.021_bib0035","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.25648","article-title":"Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications","volume":"117","author":"Pinilla-Ibarz","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2012.10.021_bib0040","series-title":"Patient-reported outcome measures: use in medical product development to support labeling claims","author":"US Food Drug Administration: Guidance for Industry","year":"2009"},{"key":"10.1016\/j.leukres.2012.10.021_bib0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.critrevonc.2011.02.007","article-title":"Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes","volume":"81","author":"Efficace","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.leukres.2012.10.021_bib0050","doi-asserted-by":"crossref","unstructured":"Trask PC, Cella D, Powell C, Reisman C, Whiteley J, Kelly V. Health-related quality of life in chronic myeloid leukemia. Leuk Res; http:\/\/dx.doi.org\/10.1016\/j.leukres.2012.09.013, in press.","DOI":"10.1016\/j.leukres.2012.09.013"},{"key":"10.1016\/j.leukres.2012.10.021_bib0055","doi-asserted-by":"crossref","unstructured":"Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HSL, Small BJ, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer; http:\/\/dx.doi.org\/10.1007\/s00520-012-1630-5, in press.","DOI":"10.1007\/s00520-012-1630-5"},{"key":"10.1016\/j.leukres.2012.10.021_bib0060","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-012-1458-6","article-title":"Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?: GIMEMA and EORTC quality of life group","volume":"91","author":"Efficace","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2012.10.021_bib0065","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.leukres.2011.10.011","article-title":"Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia","volume":"36","author":"Trask","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2012.10.021_bib0070","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3109\/10428194.2011.560310","article-title":"Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia","volume":"52","author":"Aziz","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2012.10.021_bib0075","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.10.021_bib0080","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study","volume":"21","author":"Hahn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.10.021_bib0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1053\/shem.2003.50039","article-title":"Quality of life on imatinib","volume":"40","author":"Hahn","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2012.10.021_bib0090","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.10.021_bib0095","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2003.12.121","article-title":"Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials\u2014does HRQOL evaluation in prostate cancer research inform clinical decision making?","volume":"21","author":"Efficace","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.10.021_bib0100","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1996.14.2.671","article-title":"Outcomes of cancer treatment for technology assessment and cancer treatment guidelines, American Society of Clinical Oncology","volume":"14","author":"ASCO","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.10.021_bib0105","unstructured":"National Cancer Institute. The NCI Strategic Plan for Leading the Nation. To Eliminate the Suffering and Death due to Cancer. National Institutes of Health Publication No. 06-5773. http:\/\/strategicplan.nci.nih.gov\/pdf\/nci_2007_strategic_plan.pdf."},{"key":"10.1016\/j.leukres.2012.10.021_bib0110","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/asheducation-2011.1.128","article-title":"Managing chronic myeloid leukemia as a chronic disease","author":"Hochhaus","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.leukres.2012.10.021_bib0115","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3324\/haematol.11710","article-title":"Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here?","volume":"92","author":"Efficace","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2012.10.021_bib0120","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2008.03.017","article-title":"Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials \u2013 a systematic review to evaluate the added value in supporting clinical decision making","volume":"44","author":"Efficace","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.leukres.2012.10.021_bib0125","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.10.021_bib0130","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/MLR.0b013e31819a5acc","article-title":"Physician communication and patient adherence to treatment: a meta-analysis","volume":"47","author":"Zolnierek","year":"2009","journal-title":"Med Care"},{"key":"10.1016\/j.leukres.2012.10.021_bib0135","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bjc.2012.348","article-title":"Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study","volume":"107","author":"Efficace","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2012.10.021_bib0140","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1200\/JCO.2008.20.9502","article-title":"Health-related quality of life among long-term rectal cancer survivors with an ostomy: manifestations by sex","volume":"27","author":"Krouse","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.10.021_bib0145","first-page":"104","article-title":"Observational study for evaluation of quality of life in patients with chronic myeloid leukemia (CML) in use of Gleevec\u00ae (Imatinib Mesilate)","author":"Pasquini","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261200433X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261200433X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:58:07Z","timestamp":1758934687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261200433X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S014521261200433X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.10.021","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2012.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}